We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

56 hedge funds and large institutions have $1.02M invested in Navidea Biopharmaceuticals Inc. in 2018 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 7

6% more funds holding

Funds holding: 53 → 56 (+3)

14% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 7

74% less capital invested

Capital invested by funds: $3.91M → $1.02M (-$2.9M)

Holders
56
Holders Change
+3
Holders Change %
+5.66%
% of All Funds
1.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
6
Reduced
7
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
+$13.1K
2
CAG
Csenge Advisory Group
Florida
+$8.24K
3
Millennium Management
Millennium Management
New York
+$4.04K
4
SS
Simplicity Solutions
Minnesota
+$3.13K
5
Bank of America
Bank of America
North Carolina
+$2.58K

Top Sellers

Rank Fund Capital Flow
1
CWM
Cornerstone Wealth Management
Missouri
-$1.13M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$282K
3
HIIFS
Harel Insurance Investments & Financial Services
Israel
-$180K
4
SFS
Sowell Financial Services
Arkansas
-$55K
5
Goldman Sachs
Goldman Sachs
New York
-$31K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$383K -$282K -68,377 -27%
BlackRock
2
BlackRock
New York
$255K +$1.78K +433 +0.3%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$73K – – –
California Public Employees Retirement System
4
California Public Employees Retirement System
California
$38K – – –
Northern Trust
5
Northern Trust
Illinois
$26K – – –
ACM
6
Allred Capital Management
Texas
$21K +$43.1K +10,449 New
WS
7
Wedbush Securities
California
$20K – – –
Morgan Stanley
8
Morgan Stanley
New York
$16K – – –
Bank of New York Mellon
9
Bank of New York Mellon
New York
$15K – – –
Citadel Advisors
10
Citadel Advisors
Florida
$13K -$907 -220 -3%
Creative Planning
11
Creative Planning
Kansas
$12K – – –
Cambridge Investment Research Advisors
12
Cambridge Investment Research Advisors
Iowa
$12K +$132 +32 +0.5%
VF
13
Virtu Financial
New York
$10K -$2.21K -536 -10%
Wells Fargo
14
Wells Fargo
California
$10K – – –
UBS Group
15
UBS Group
Switzerland
$9K +$882 +214 +5%
State Street
16
State Street
Massachusetts
$7K – – –
TSS
17
Two Sigma Securities
New York
$7K +$13.1K +3,190 New
CWM
18
Cabot Wealth Management
Massachusetts
$6K – – –
SW
19
SVB Wealth
Massachusetts
$5K – – –
Tudor Investment Corp
20
Tudor Investment Corp
Connecticut
$5K – – –
Jane Street
21
Jane Street
New York
$5K +$206 +50 +2%
Bank of America
22
Bank of America
North Carolina
$5K +$2.58K +625 +36%
SWA
23
Stratos Wealth Advisors
Ohio
$5K +$10.3K +2,504 New
HighTower Advisors
24
HighTower Advisors
Illinois
$4K -$7.24K -1,756 -43%
SWP
25
Stratos Wealth Partners
Ohio
$4K -$1.13K -275 -12%
1
2 3

NAVB Hedge Fund Activity: Q4 2018 in Review

56 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q4 2018, worth a combined $1.02M — down 74% from $3.91M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new NAVB positions and 7 closed out — a net gain of 3 holders — while 6 added to existing stakes and 7 trimmed.

The largest buyer was Two Sigma Securities, opening a new position worth an estimated $13.1K. The largest seller was Cornerstone Wealth Management, exiting entirely with an estimated $1.13M sold.

  • 56 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q4 2018, up from 53 in Q3 2018.
  • Funds reported $1.02M of Navidea Biopharmaceuticals Inc. stock for Q4 2018, down 74% quarter-over-quarter.
  • 10 funds opened new Navidea Biopharmaceuticals Inc. positions in Q4 2018 and 7 closed out, a net change of +3 holders.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q4 2018 was Two Sigma Securities, an estimated $13.1K added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q4 2018 was Cornerstone Wealth Management, an estimated $1.13M sold.

Based on aggregated 13F filings for Q4 2018.